Telix’s Illuccix® Gains Regulatory Approval in Brazil, Expanding Prostate Cancer Imaging Access

Telix Pharmaceuticals has secured regulatory approval from ANVISA for Illuccix®, its prostate cancer imaging agent, marking a significant milestone for cancer diagnostics in Brazil. As the first PSMA-PET imaging agent fully approved in the country, Illuccix® enables precise detection of prostate-specific membrane antigen (PSMA) positive lesions in patients with suspected metastasis or recurrence. This approval is set to enhance access to advanced prostate cancer imaging nationwide, supported by Telix’s partnership with R2PHARMA, a leading Brazilian manufacturer and distributor of radiopharmaceuticals.

To further expand its presence in Brazil, Telix has formed a joint venture (JV) with R2PHARMA to manufacture and distribute radiopharmaceuticals for both clinical and commercial use. With Brazil’s radiopharmaceutical market projected to reach $330 million in the coming decade, this collaboration aims to introduce cutting-edge theranostic solutions for cancer and other diseases. Telix Innovations Brazil, Ltda. will oversee commercialization, ensuring broader patient access to life-saving imaging and therapeutic technologies.